A recent study on batiraxcept, a soluble AXL signaling inhibitor, highlights its potential in suppressing prostate cancer bone metastases.
Using patient-derived xenograft models, researchers showed that batiraxcept, alone or in combination with docetaxel or carboplatin, significantly reduced tumor growth in the bone and prevented lung metastases. High AXL phosphorylation in bone metastases correlated with poorer survival, while batiraxcept treatment disrupted key pathways like PI3K, JAK, and MAPK, and downregulated cancer stemness genes.
These findings support the use of batiraxcept as a promising treatment for advanced prostate cancer. Notably, the same drug will also be tested in a Phase 3 trial for clear cell renal cell carcinoma (ccRCC), adding to its potential significance in oncology.
Androgen Receptor Activity (ARA) for BAT
Oligometastatic prostate cancer: Reality or figment of imagination?
Doxycycline